LifeStance Health Group misses by $0.17, beats on revs; guides Q3 revs below consensus; guides Q4 (Dec) revs above consensus
- Reports Q2 (Jun) loss of $0.22 per share, $0.17 worse than the S&P Capital IQ Consensus of ($0.05); revenues rose 253.2% year/year to $160.55 mln vs the $155.92 mln S&P Capital IQ Consensus.
- Co issues downside guidance for Q3, sees Q3 revs of $168-173 mln vs. $175.72 mln S&P Capital IQ Consensus.
- Co issues upside guidance for Q4 (Dec), sees Q4 (Dec) revs of $196-201 mln vs. $193.03 mln S&P Capital IQ Consensus.
No comments:
Post a Comment